Debu Tripathy, M.D.

March 18, 2023

Personalized medicine means not only more powerful drugs for cancers, but also more precise mechanisms that target the specific consequence of mutations and other alterations that drive cancer cell growth, sparing normal cells.

December 30, 2022

Good science, along with creativity in applying and testing it properly, can be successful against all odds for patients with cholangiocarcinoma.

December 29, 2022

Discovering different genetic mutations to target ... continues to add to the excitement.

November 15, 2022

Does lung cancer screening continue after a person is finished with treatment and moves in to the survivorship stage?

October 23, 2022

October 21, 2022

Enhertu's FDA approval marked a major milestone in the breast cancer space, as it was the first drug to be approved for patients with HER2-low disease.

September 22, 2022

Maintenance therapy helps deter undetectable cancer that may exist after initial treatment.

June 26, 2022

The stories in this issue of CURE illustrate how patients with cancer have become partners in therapeutic advances.

November 23, 2021

It is my hope that the cancer field continues to grow the novel therapy for not only patients with lung cancer, but well beyond. It is critical that the public be aware of how research and clinical trials are catalysts to better the outcomes of patients with cancer.

October 19, 2021

Engineered cell technology is an example of ingenuity that brings together cutting-edge laboratory science and clinical trials to address aggressive cancers.

October 14, 2021

Brain metastases are a pattern of spread we are seeing more for many tumor types as patients are living longer with metastatic cancer and we more readily use an array of brain imaging technologies when needed.

September 26, 2021

It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.

August 04, 2021

Read more about the current research for the disease, as well as how these advances impact the patients diagnosed with it.

June 28, 2021

Patients with cancer who are treated with checkpoint inhibitors or immunotherapy, along with other treatments, run the risk of developing ILD as a side effect.

May 09, 2021

Sophisticated analyses can predict which gut microbiome profile may lead to better outcomes to immunotherapy for patients with advanced melanoma.

May 01, 2021

Over the past few years, lung cancer has changed significantly with improving outcomes, particularly attributable to immunotherapy, but how do we continue that trend?

March 27, 2021

It is difficult for anyone to receive a cancer diagnosis, but when someone who is younger than average finds out they have gastrointestinal cancer, they may face other challenges.

March 25, 2021

Although COVID-19 has shaken our lives in so many ways, it’s important to keep our health one of our top priorities while also staying safe. We must find widely acceptable ways to screen for cancer in this new era so that we don’t turn the clock back on the gains we have made in the past few decades.

February 27, 2021

Over the past decade, advances in both diagnostics and therapeutics in a variety of blood cancers have turned certain diseases into chronic conditions.

November 23, 2020

As our understanding of lung cancer broadens, experts are now looking to rare genomic alterations that lead to aggressive lung cancer.

October 22, 2020

Treatments like kinase inhibitors are changing the options patient may have for when their breast cancer spreads to the brain.

October 04, 2020

Finding balance to detect and treat prostate cancer without overtreatment is important for patients.

September 25, 2020

Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).

August 30, 2020

The evolving understanding of cancer genetics is allowing for clinicians to look at how to move rare cancer treatments, and identifications, forward.

August 01, 2020

Telemedicine has been a growing trend in the cancer landscape, but due to the COVID-19 pandemic, it is an essential part of cancer care. And here's why it's here to stay.

July 06, 2020

Immunotherapy is a wonderful testament to the benefits that arise from our growing understanding of the incredibly intricate human immune system.

May 24, 2020

In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.

April 10, 2020

CURE®’s Editor-in-Chief weighs in on how the treatment and detection landscape needs to be refined to help patients with ovarian cancer.

March 09, 2020

Targeted therapies have changed the landscape of cancer care, and now, hope for remission is a possibility for certain patients with acute myeloid leukemia with new approved therapies.

February 18, 2020

PARP Inhibitors are opening new doors in cancer treatment by targeting vulnerabilities in cancer that researchers are beginning to understand better.